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Abstract Bronchial provocation testing uses a variety of
direct and indirect inhalational challenges to evaluate air-
way hyperreactivity. Mannitol, a simple, easy-to-adminis-
ter hypertonic stimulus available in many countries, is
currently under review by the FDA in the US. Healthy
subjects show no airway response to inhaled mannitol;
asthmatic patients respond with airway narrowing similar
to challenges with hypertonic saline and exercise. Mannitol
challenge also has a tussive effect that is independent of
bronchoconstriction, suggesting different physiologic
pathways. Patients with chronic cough show increased
sensitivity to mannitol, and mannitol testing may be useful
for evaluating heterogeneity in the cough response.
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Introduction
Bronchial provocation testing may be employed for a
variety of purposes, but it is most commonly used to assess
the tendency of the bronchi to narrow in response to
exogenous stimuli. Testing can be done by direct and
indirect challenges using a number of different agents [1]
(Table 1).
Methacholine aerosol inhalation is the prototype of a
direct inhalation challenge. Bronchoconstriction following
inhalation results from the direct action of methacholine on
acetylcholine receptors in airway smooth muscle. Metha-
choline bronchoprovocation challenge is highly sensitive in
identifying bronchial hyperreactivity, and a negative test is
often used to exclude asthma [1].
Indirect challenges simulate airway responses to specific
physiologic situations such as exercise [1, 2]. The most
recent indirect challenge is the mannitol (MAN) dry
powder challenge, which is available as a standardized test
kit in some countries [3]. It is currently in review, but not
approved, by the Food and Drug Administration for use in
the US. The kit includes prefilled capsules with mannitol in
escalating doses, to be administered in an easy-to-use,
handheld dry powder device. The safety and efficacy of
MAN dry powder inhalation challenge have been estab-
lished in large Phase III trials involving healthy subjects
and patients with asthma [3, 4].
Mannitol Inhalation Challenge
Mannitol is a hypertonic stimulus, and inhalation is thought
to exert an osmotic effect within the airway that subse-
quently leads to the release of inflammatory mediators
from mast cells, basophils, and human lung fragments [5].
In asthmatic patients this leads to airway narrowing similar
to that observed with hypertonic saline and exercise chal-
lenge. Healthy, nonasthmatic subjects show no airway
response to inhaled mannitol [3–5].
A positive response to mannitol is used to identify
patients who have exercise-induced bronchoconstriction
(EIB), with or without chronic symptoms of asthma. A
negative response suggests that asthma is not present or, in
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some cases, that it is mild with intermittent symptoms or
well-treated [3, 4, 6].
The simplicity of the mannitol challenge suggests that
there may be some advantages over other bronchoprovo-
cation tests. Mannitol is given by a handheld dry powder
inhaler (DPI), so there is no specialized equipment required
for the doctor’s office. Use of the DPI also makes the test
easy for patients to learn and permits the test to be con-
ducted quickly [4, 6]. These advantages were recently
confirmed in a study assessing the sensitivity and speci-
ficity of mannitol to identify EIB as a manifestation of
bronchial hyperreactivity in a highly selected population of
possible asthmatics with a normal FEV1 [4]. A comparison
was made with methacholine. Mannitol and methacholine
were therapeutically equivalent to identify EIB and estab-
lish a clinician’s diagnosis of asthma. However, in addition
to not requiring specialized equipment, the mannitol chal-
lenge was more reproducible and took less time to perform
than the methacholine test [4]. Only 43.5% of the subjects
had a positive response to exercise as defined by at least a
10% reduction in FEV1 on at least one of two challenges
[4].
To better understand the mechanism associated with a
mannitol challenge, Brannan et al. [5] studied 12 asthmatic
and 9 nonasthmatic subjects for evidence of mast cell
activation and leukotriene release. They measured urinary
excretion of leukotriene (LT) E4 and prostaglandin (PG) D2
metabolites (and mast cell markers) N-methylhistamine
and 9a,11b, PGF2 at 60 min before and 90 min after
mannitol inhalation. Airway narrowing provoked by man-
nitol challenge in asthmatic subjects was associated with
increased urinary excretion of 9a,11b, PGF2. Excretion of
this PGD2 metabolite is an index of mast cell activation,
and following mannitol challenge it is probably secondary
to increased osmolarity of the airway surface liquid [5].
Urinary excretion of N-methylhistamine was not signifi-
cantly affected by mannitol.
The data support earlier work showing changes in air-
way sensitivity to mannitol in the presence of various
mediator antagonists. Interestingly, in subjects with asthma
the histamine antagonist fexofenadine (2 9 180 mg over
14 h) reduced airway sensitivity to mannitol, while the
leukotriene antagonist montelukast (3 9 10 mg over 36 h)
caused a faster recovery of lung function to baseline post-
challenge but had no effect on sensitivity [7]. The same
mediators and time sequence of release have been reported
with exercise-induced asthma, suggesting a similar mech-
anism of action [5].
The mast cell stabilizer nedocromil sodium (8 mg,
10 min prechallenge), also has been reported to signifi-
cantly reduce bronchoconstriction to mannitol inhalation in
subjects with exercise-induced asthma [8]. More recently,
both cromolyn sodium (40 mg, 15 min prechallenge),
another mast cell stabilizer, and formoterol (24 mcg,
15 min prechallenge), a long-acting bronchodilator, were
shown to protect against the change in 9a,11b, PGF2
concomitant with a reduction in the mannitol-induced fall
in FEV1 (by 35 and 95%, respectively) [9].
Using Mannitol to Assess Cough
One of the early observations in the development of the
mannitol challenge was that it has a tussive effect. Like
other indirect bronchoprovocation challenges, asthmatics
cough more than healthy controls in response to mannitol,
and the tussive effect is independent of the bronchocon-
strictive effect, suggesting different physiological mecha-
nisms [10]. However, the simplicity of the mannitol
challenge compared to other indirect bronchoprovocation
tests makes it a potentially useful tool for evaluating air-
ways hyperresponsiveness and cough sensitivity.
A pilot study looked at the dose of mannitol needed to
provoke two or five coughs in 13 subjects with nonasth-
matic chronic cough compared to 16 healthy subjects [11].
The subjects with chronic cough showed a heightened
cough response to challenge (i.e., less mannitol needed to
provoke cough); none had airway responsiveness to man-
nitol. The findings support the hypotheses that (1) manni-
tol-provoked cough is increased in patients with
nonasthmatic chronic cough, and (2) mannitol-provoked
cough is independent of mannitol-provoked bronchocon-
striction. The cough response may involve indirect acti-
vation of mast cells in the superficial airway and
subsequent release or mediators that, in turn, activate local
cough receptors [11]. The separate observation that nedo-
cromil sodium failed to attenuate mannitol-induced cough,
in contrast to mannitol-induced bronchoconstriction, sup-
ports the lack of direct involvement of mast cell pathways
[12].
Similar findings have been reported for capsaicin, a
common test for studying induced cough. Capsaicin, the
‘‘hot’’ ingredient in red pepper, is known to stimulate
unmyelinated C fibers in the sensory nervous system [13].
Studies have shown that coughing can be induced by
capsaicin inhalation in a dose-dependent manner in healthy
Table 1 Agents commonly used in bronchial provocation testing [1]
Indirect challenges Direct challenges
Adenosine monophosphate (AMP) Acetylcholine
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subjects and those with mild asthma, and that capsaicin
challenge does not cause dyspnea and has no effect on the
FEV1. It has been demonstrated that capsaicin-induced
cough can be blocked by local anesthetic [14–16] but not
by pretreatment with the mast cell stabilizer cromolyn
sodium [17]. These data support the separation of neuronal
pathways of coughing from bronchoconstrictive airway
responses directly related to inflammatory mediators.
Patients with increased coughing as a symptom repre-
sent a heterogeneous population. Mannitol inhalation
challenge may be useful for diagnosing and/or managing at
least three types of patients described in the literature.
Asthma Patients
Koskela et al. [10] analyzed the cough response to three
airway challenges in order to clarify whether the recording of
the provoked cough would be beneficial in the management
of asthma. They used isotonic histamine, hypertonic saline
solution, and hypertonic histamine, all delivered by an
ultrasonic nebulizer using the 2-min tidal breathing method.
Coughing during isotonic histamine challenge seemed to be
a manifestation of bronchoconstriction, but recording the
cough did not provide additional information to airflow
measurements [10]. Frequent coughing occurred during the
hypertonic challenges in the absence of bronchoconstriction.
Sensitivity to the cough-provoking effect of hypertonic
challenges was enhanced in patients with asthma and was
unrelated to airway hyperresponsiveness. These investiga-
tors, therefore, advocated that cough assessment during
hypertonic challenges could help to identify those patients
with cough-variant asthma [10].
Patients with Odor Intolerance
These patients show increased coughing and increased
cough sensitivity to inhaled capsaicin. Johansson et al. [18]
investigated the relationship between cough sensitivity to
inhaled capsaicin and odor sensitivity using a chemical
sensitivity scale for sensory hyperreactivity (CSS-SHR),
dividing subjects into four groups with different odor sen-
sitivity according to their CSS-SHR score. Of these, 137
individuals randomly received a capsaicin inhalation test in
which the number of coughs encountered 10 min from the
start of each inhalation was registered. More than 80% of
subjects with positive capsaicin inhalation scores also had
positive CSS-SHR scores; only 5% of subjects with negative
CSS-SHR scores had a positive capsaicin inhalation test. The
direct relationship between sensitivity to inhaled capsaicin
and a high CSS-SHR score makes it possible to relate sub-
jective data to objective findings [18]. Mannitol challenge of
patients with odor insensitivity and dyspnea may support the
diagnosis and lead to early and appropriate treatment.
Patients with Suspected EIB
Mannitol-induced coughing was evident in 93% of 419
subjects studied for suspected EIB as diagnosed by man-
nitol and methacholine challenges [4]. Of these, 204 (49%)
had occasional cough that did not interfere with the chal-
lenge, 178 (42%) had frequent cough that delayed admin-
istration of the next dose, and 9 (2%) had severe cough that
interfered with the challenge [4].
The studies cited above have shown heterogeneity in the
cough response to mannitol. Using a cough counter supplied
by Karmel Sonics-Israel, my coworkers and I have evalu-
ated the differences in cough response to mannitol inhala-
tion. Figure 1 illustrates the cough-response variability
among three patients. Two individuals had no cough at any
time during the challenges, while the other had a cough
throughout; all three had positive bronchoprovocation
testing with drops in FEV1 by more than 20% at premaxi-
mal doses. The variation in the cough responses probably
reflects differences in the underlying mechanisms of airway
hyperresponsiveness in these individuals, but more patients
should be studied before drawing any conclusions. Similar
findings have been reported by Dicpinigaitis et al. [19] who
reviewed the safety of capsaicin cough challenges over
20 years of clinical experience. Like the initial results to
date with mannitol, no serious adverse events were asso-
ciated with capsaicin cough-challenge testing, only minor
and transient descriptions of throat irritation. However,
heterogeneity in the cough response was observed: asth-
matics without cough did not differ from healthy volunteers
in terms of cough reflux sensitivity to capsaicin, though
differences were evident in airway reactivity. The results
from mannitol and capsaicin thus support the suggestion
that cough and bronchial responsiveness are distinct phe-
nomena mediated through unique neural pathways. Cough
monitoring during bronchial challenges may help sort out
subtypes of asthma and airway reactivity.
Mannitol as a Treatment for Cystic Fibrosis (CF)
As a hypertonic agent, mannitol inhalation may have a
beneficial effect on mucus elimination in patients with CF.
An initial study demonstrated an improvement in lung
function related to small airway obstruction and a signifi-
cant improvement in respiratory symptoms and quality of
life after a 2-week treatment with mannitol in 38 patients
[20]. The dose used was 400 mg twice daily.
The suggested mechanism for the positive action of
mannitol in CF is the same as that for nebulized hypertonic
saline treatment, i.e., osmotically induced water influx into
the bronchial lumen thereby increasing the hydration of
airway mucus so that it is cleared more effectively and
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expectorated [20]. Enhanced ciliary clearance of mucus
also should result in a sustained reduction in mucus load,
thus providing less opportunity for proliferation of bacteria
and infection leading to less antibiotic use and fewer hos-
pitalizations. Long-term studies have been proposed and
are presently being assessed by investigative protocols.
In summary, mannitol is a simple, easy-to-administer
indirect, inhalation challenge test. Sensitivity to mannitol is
increased in patients with asthma and in patients with
chronic cough, but mannitol-provoked cough occurs via
different pathways than mannitol-provoked bronchocon-
striction. Mannitol challenge testing may help sort out the
heterogeneity in cough and bronchoconstrictive responses
in certain patient populations.
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